Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies
Purpose Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [ 18 F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments. Methods Fifty-three patients enrolled in...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2021-11, Vol.48 (12), p.3940-3950 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3950 |
|---|---|
| container_issue | 12 |
| container_start_page | 3940 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 48 |
| creator | Krebs, Simone Mauguen, Audrey Yildirim, Onur Hatzoglou, Vaios Francis, Jasmine H. Schaff, Lauren R. Mellinghoff, Ingo K. Schöder, Heiko Grommes, Christian |
| description | Purpose
Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [
18
F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments.
Methods
Fifty-three patients enrolled in a prospective clinical trial and underwent brain PET before receiving single-agent ibrutinib or ibrutinib in combination with methotrexate with or without rituximab. [
18
F]FDG uptake in these lesions was quantified by drawing PET volumes of interest around up to five [
18
F]FDG-avid lesions per patient (with uptake greater than surrounding brain). We measured standardized uptake values (SUV
max
), metabolic tumor volumes, total lesion glycolysis (TLG), and the sum thereof in these lesions. We analyzed the relationship between PET parameters and mutation status, overall response rates, and progression-free survival (PFS).
Results
Thirty-eight patients underwent single-agent therapy and 15 received combination therapy. On PET, 15/53 patients had no measurable disease. In the other 38 patients, a total of 71 lesions were identified on PET. High-intensity [
18
F]FDG uptake and a larger volume of [
18
F]FDG-avid disease were inversely related to treatment outcome (
p
≤ 0.005). In univariable analysis, PFS was linearly correlated with all PET parameters, with stronger association when sum-values were used. A multivariable model showed that risk of progression increased by 9% for every 5-unit increase in sumSUV
max
(hazard ratio = 1.09 [95% CI: 1.04 to 1.14]).
Conclusion
Higher lesional metabolic parameters are inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUV
max
emerged as a strong independent prognostic factor.
Trial registration
NCT02315326;
https://clinicaltrials.gov/ct2/show/NCT02315326?term=NCT02315326&draw=2&rank=1 |
| doi_str_mv | 10.1007/s00259-021-05386-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8484020</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2524879039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-e746a156494af1639980ce2846df757e121861e83de899c1444c0589f3bc12e73</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EoqXwBzggS1y4hI4dxx8XJLR0C1IFlVhOCFmOd7LrKolTO1nUf0-WLcvHgZNHmmcez-gl5DmD1wxAnWcAXpkCOCugKrUs4AE5ZZKZQoE2D4-1ghPyJOcbAKa5No_JSVkaKUGrU4LXKW76mMfg6c61E9LY0K9ML78t313S64vV-WJFQ08HNwbsx0y_h3FLFx8_0_auG7axczShx7AL_YaGOk1j6ENd1C7jmo5bTG4ImJ-SR41rMz67f8_Il-XFavG-uPp0-WHx9qrwQomxQCWkY5UURriGydIYDR65FnLdqEoh40xLhrpcozbGMyGEh0qbpqw946jKM_Lm4B2musO1nzdOrrVDCp1Ldza6YP_u9GFrN3FntdACOMyCV_eCFG8nzKPtQvbYtq7HOGXLKy60MlCaGX35D3oTp9TP582UUoZJXe2F_ED5FHNO2ByXYWD3KdpDinZO0f5M0e6HXvx5xnHkV2wzUB6APLf6Dabff_9H-wNcjab3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2577916850</pqid></control><display><type>article</type><title>Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Krebs, Simone ; Mauguen, Audrey ; Yildirim, Onur ; Hatzoglou, Vaios ; Francis, Jasmine H. ; Schaff, Lauren R. ; Mellinghoff, Ingo K. ; Schöder, Heiko ; Grommes, Christian</creator><creatorcontrib>Krebs, Simone ; Mauguen, Audrey ; Yildirim, Onur ; Hatzoglou, Vaios ; Francis, Jasmine H. ; Schaff, Lauren R. ; Mellinghoff, Ingo K. ; Schöder, Heiko ; Grommes, Christian</creatorcontrib><description>Purpose
Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [
18
F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments.
Methods
Fifty-three patients enrolled in a prospective clinical trial and underwent brain PET before receiving single-agent ibrutinib or ibrutinib in combination with methotrexate with or without rituximab. [
18
F]FDG uptake in these lesions was quantified by drawing PET volumes of interest around up to five [
18
F]FDG-avid lesions per patient (with uptake greater than surrounding brain). We measured standardized uptake values (SUV
max
), metabolic tumor volumes, total lesion glycolysis (TLG), and the sum thereof in these lesions. We analyzed the relationship between PET parameters and mutation status, overall response rates, and progression-free survival (PFS).
Results
Thirty-eight patients underwent single-agent therapy and 15 received combination therapy. On PET, 15/53 patients had no measurable disease. In the other 38 patients, a total of 71 lesions were identified on PET. High-intensity [
18
F]FDG uptake and a larger volume of [
18
F]FDG-avid disease were inversely related to treatment outcome (
p
≤ 0.005). In univariable analysis, PFS was linearly correlated with all PET parameters, with stronger association when sum-values were used. A multivariable model showed that risk of progression increased by 9% for every 5-unit increase in sumSUV
max
(hazard ratio = 1.09 [95% CI: 1.04 to 1.14]).
Conclusion
Higher lesional metabolic parameters are inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUV
max
emerged as a strong independent prognostic factor.
Trial registration
NCT02315326;
https://clinicaltrials.gov/ct2/show/NCT02315326?term=NCT02315326&draw=2&rank=1</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-021-05386-0</identifier><identifier>PMID: 33966087</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adenine - analogs & derivatives ; Brain ; Cardiology ; Computed tomography ; Fluorine isotopes ; Fluorodeoxyglucose F18 ; Glycolysis ; Health services ; Humans ; Imaging ; Inhibitor drugs ; Lesions ; Lymphoma ; Lymphoma, Non-Hodgkin ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metabolism ; Methotrexate ; Mutation ; Neuroimaging ; Nuclear Medicine ; Oncology ; Oncology – Brain ; Original Article ; Orthopedics ; Parameters ; Patients ; Piperidines ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Prognosis ; Prospective Studies ; Radiology ; Retrospective Studies ; Rituximab ; Targeted cancer therapy ; Tumor Burden</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2021-11, Vol.48 (12), p.3940-3950</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-e746a156494af1639980ce2846df757e121861e83de899c1444c0589f3bc12e73</citedby><cites>FETCH-LOGICAL-c474t-e746a156494af1639980ce2846df757e121861e83de899c1444c0589f3bc12e73</cites><orcidid>0000-0003-3236-6093 ; 0000-0003-0252-0694 ; 0000-0002-7485-0441 ; 0000-0002-9909-4531 ; 0000-0002-4664-670X ; 0000-0002-5170-4185 ; 0000-0002-4347-8149</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-021-05386-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-021-05386-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33966087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krebs, Simone</creatorcontrib><creatorcontrib>Mauguen, Audrey</creatorcontrib><creatorcontrib>Yildirim, Onur</creatorcontrib><creatorcontrib>Hatzoglou, Vaios</creatorcontrib><creatorcontrib>Francis, Jasmine H.</creatorcontrib><creatorcontrib>Schaff, Lauren R.</creatorcontrib><creatorcontrib>Mellinghoff, Ingo K.</creatorcontrib><creatorcontrib>Schöder, Heiko</creatorcontrib><creatorcontrib>Grommes, Christian</creatorcontrib><title>Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [
18
F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments.
Methods
Fifty-three patients enrolled in a prospective clinical trial and underwent brain PET before receiving single-agent ibrutinib or ibrutinib in combination with methotrexate with or without rituximab. [
18
F]FDG uptake in these lesions was quantified by drawing PET volumes of interest around up to five [
18
F]FDG-avid lesions per patient (with uptake greater than surrounding brain). We measured standardized uptake values (SUV
max
), metabolic tumor volumes, total lesion glycolysis (TLG), and the sum thereof in these lesions. We analyzed the relationship between PET parameters and mutation status, overall response rates, and progression-free survival (PFS).
Results
Thirty-eight patients underwent single-agent therapy and 15 received combination therapy. On PET, 15/53 patients had no measurable disease. In the other 38 patients, a total of 71 lesions were identified on PET. High-intensity [
18
F]FDG uptake and a larger volume of [
18
F]FDG-avid disease were inversely related to treatment outcome (
p
≤ 0.005). In univariable analysis, PFS was linearly correlated with all PET parameters, with stronger association when sum-values were used. A multivariable model showed that risk of progression increased by 9% for every 5-unit increase in sumSUV
max
(hazard ratio = 1.09 [95% CI: 1.04 to 1.14]).
Conclusion
Higher lesional metabolic parameters are inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUV
max
emerged as a strong independent prognostic factor.
Trial registration
NCT02315326;
https://clinicaltrials.gov/ct2/show/NCT02315326?term=NCT02315326&draw=2&rank=1</description><subject>Adenine - analogs & derivatives</subject><subject>Brain</subject><subject>Cardiology</subject><subject>Computed tomography</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glycolysis</subject><subject>Health services</subject><subject>Humans</subject><subject>Imaging</subject><subject>Inhibitor drugs</subject><subject>Lesions</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Methotrexate</subject><subject>Mutation</subject><subject>Neuroimaging</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – Brain</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Parameters</subject><subject>Patients</subject><subject>Piperidines</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Radiology</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><subject>Tumor Burden</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1v1DAQhi0EoqXwBzggS1y4hI4dxx8XJLR0C1IFlVhOCFmOd7LrKolTO1nUf0-WLcvHgZNHmmcez-gl5DmD1wxAnWcAXpkCOCugKrUs4AE5ZZKZQoE2D4-1ghPyJOcbAKa5No_JSVkaKUGrU4LXKW76mMfg6c61E9LY0K9ML78t313S64vV-WJFQ08HNwbsx0y_h3FLFx8_0_auG7axczShx7AL_YaGOk1j6ENd1C7jmo5bTG4ImJ-SR41rMz67f8_Il-XFavG-uPp0-WHx9qrwQomxQCWkY5UURriGydIYDR65FnLdqEoh40xLhrpcozbGMyGEh0qbpqw946jKM_Lm4B2musO1nzdOrrVDCp1Ldza6YP_u9GFrN3FntdACOMyCV_eCFG8nzKPtQvbYtq7HOGXLKy60MlCaGX35D3oTp9TP582UUoZJXe2F_ED5FHNO2ByXYWD3KdpDinZO0f5M0e6HXvx5xnHkV2wzUB6APLf6Dabff_9H-wNcjab3</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Krebs, Simone</creator><creator>Mauguen, Audrey</creator><creator>Yildirim, Onur</creator><creator>Hatzoglou, Vaios</creator><creator>Francis, Jasmine H.</creator><creator>Schaff, Lauren R.</creator><creator>Mellinghoff, Ingo K.</creator><creator>Schöder, Heiko</creator><creator>Grommes, Christian</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3236-6093</orcidid><orcidid>https://orcid.org/0000-0003-0252-0694</orcidid><orcidid>https://orcid.org/0000-0002-7485-0441</orcidid><orcidid>https://orcid.org/0000-0002-9909-4531</orcidid><orcidid>https://orcid.org/0000-0002-4664-670X</orcidid><orcidid>https://orcid.org/0000-0002-5170-4185</orcidid><orcidid>https://orcid.org/0000-0002-4347-8149</orcidid></search><sort><creationdate>20211101</creationdate><title>Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies</title><author>Krebs, Simone ; Mauguen, Audrey ; Yildirim, Onur ; Hatzoglou, Vaios ; Francis, Jasmine H. ; Schaff, Lauren R. ; Mellinghoff, Ingo K. ; Schöder, Heiko ; Grommes, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-e746a156494af1639980ce2846df757e121861e83de899c1444c0589f3bc12e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Brain</topic><topic>Cardiology</topic><topic>Computed tomography</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glycolysis</topic><topic>Health services</topic><topic>Humans</topic><topic>Imaging</topic><topic>Inhibitor drugs</topic><topic>Lesions</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Methotrexate</topic><topic>Mutation</topic><topic>Neuroimaging</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – Brain</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Parameters</topic><topic>Patients</topic><topic>Piperidines</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Radiology</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krebs, Simone</creatorcontrib><creatorcontrib>Mauguen, Audrey</creatorcontrib><creatorcontrib>Yildirim, Onur</creatorcontrib><creatorcontrib>Hatzoglou, Vaios</creatorcontrib><creatorcontrib>Francis, Jasmine H.</creatorcontrib><creatorcontrib>Schaff, Lauren R.</creatorcontrib><creatorcontrib>Mellinghoff, Ingo K.</creatorcontrib><creatorcontrib>Schöder, Heiko</creatorcontrib><creatorcontrib>Grommes, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krebs, Simone</au><au>Mauguen, Audrey</au><au>Yildirim, Onur</au><au>Hatzoglou, Vaios</au><au>Francis, Jasmine H.</au><au>Schaff, Lauren R.</au><au>Mellinghoff, Ingo K.</au><au>Schöder, Heiko</au><au>Grommes, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>48</volume><issue>12</issue><spage>3940</spage><epage>3950</epage><pages>3940-3950</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [
18
F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments.
Methods
Fifty-three patients enrolled in a prospective clinical trial and underwent brain PET before receiving single-agent ibrutinib or ibrutinib in combination with methotrexate with or without rituximab. [
18
F]FDG uptake in these lesions was quantified by drawing PET volumes of interest around up to five [
18
F]FDG-avid lesions per patient (with uptake greater than surrounding brain). We measured standardized uptake values (SUV
max
), metabolic tumor volumes, total lesion glycolysis (TLG), and the sum thereof in these lesions. We analyzed the relationship between PET parameters and mutation status, overall response rates, and progression-free survival (PFS).
Results
Thirty-eight patients underwent single-agent therapy and 15 received combination therapy. On PET, 15/53 patients had no measurable disease. In the other 38 patients, a total of 71 lesions were identified on PET. High-intensity [
18
F]FDG uptake and a larger volume of [
18
F]FDG-avid disease were inversely related to treatment outcome (
p
≤ 0.005). In univariable analysis, PFS was linearly correlated with all PET parameters, with stronger association when sum-values were used. A multivariable model showed that risk of progression increased by 9% for every 5-unit increase in sumSUV
max
(hazard ratio = 1.09 [95% CI: 1.04 to 1.14]).
Conclusion
Higher lesional metabolic parameters are inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUV
max
emerged as a strong independent prognostic factor.
Trial registration
NCT02315326;
https://clinicaltrials.gov/ct2/show/NCT02315326?term=NCT02315326&draw=2&rank=1</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33966087</pmid><doi>10.1007/s00259-021-05386-0</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3236-6093</orcidid><orcidid>https://orcid.org/0000-0003-0252-0694</orcidid><orcidid>https://orcid.org/0000-0002-7485-0441</orcidid><orcidid>https://orcid.org/0000-0002-9909-4531</orcidid><orcidid>https://orcid.org/0000-0002-4664-670X</orcidid><orcidid>https://orcid.org/0000-0002-5170-4185</orcidid><orcidid>https://orcid.org/0000-0002-4347-8149</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2021-11, Vol.48 (12), p.3940-3950 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8484020 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenine - analogs & derivatives Brain Cardiology Computed tomography Fluorine isotopes Fluorodeoxyglucose F18 Glycolysis Health services Humans Imaging Inhibitor drugs Lesions Lymphoma Lymphoma, Non-Hodgkin Medical prognosis Medicine Medicine & Public Health Metabolism Methotrexate Mutation Neuroimaging Nuclear Medicine Oncology Oncology – Brain Original Article Orthopedics Parameters Patients Piperidines Positron emission tomography Positron Emission Tomography Computed Tomography Prognosis Prospective Studies Radiology Retrospective Studies Rituximab Targeted cancer therapy Tumor Burden |
| title | Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A41%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20%5B18F%5DFDG%20PET/CT%20in%20patients%20with%20CNS%20lymphoma%20receiving%20ibrutinib-based%20therapies&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Krebs,%20Simone&rft.date=2021-11-01&rft.volume=48&rft.issue=12&rft.spage=3940&rft.epage=3950&rft.pages=3940-3950&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-021-05386-0&rft_dat=%3Cproquest_pubme%3E2524879039%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2577916850&rft_id=info:pmid/33966087&rfr_iscdi=true |